VBI Vaccines Inc (NASDAQ:VBIV) – Investment analysts at Oppenheimer issued their FY2023 earnings estimates for shares of VBI Vaccines in a research note issued on Monday, August 12th. Oppenheimer analyst L. Gershell forecasts that the biopharmaceutical company will earn ($0.21) per share for the year. Oppenheimer currently has a “Buy” rating and a $5.00 target price on the stock.
A number of other equities analysts also recently issued reports on VBIV. Zacks Investment Research upgraded VBI Vaccines from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research note on Thursday, May 9th. BMO Capital Markets cut their price target on VBI Vaccines to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, June 18th. Finally, ValuEngine upgraded VBI Vaccines from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
VBIV stock opened at $0.62 on Wednesday. The company has a market capitalization of $64.89 million, a P/E ratio of -0.64 and a beta of 0.41. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.94 and a current ratio of 1.99. VBI Vaccines has a 52-week low of $0.57 and a 52-week high of $2.78. The business has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $1.58.
VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $0.64 million during the quarter, compared to the consensus estimate of $0.60 million. VBI Vaccines had a negative return on equity of 71.46% and a negative net margin of 1,582.45%.
In other VBI Vaccines news, major shareholder Life Sciences Maste Perceptive bought 1,000,000 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were purchased at an average price of $0.62 per share, for a total transaction of $620,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeff Baxter bought 144,000 shares of the business’s stock in a transaction dated Wednesday, June 19th. The stock was acquired at an average price of $0.73 per share, for a total transaction of $105,120.00. Following the purchase, the chief executive officer now directly owns 458,255 shares in the company, valued at $334,526.15. The disclosure for this purchase can be found here. Insiders bought a total of 1,160,000 shares of company stock worth $739,600 in the last 90 days. Company insiders own 10.50% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. boosted its position in VBI Vaccines by 6.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 1,437,549 shares of the biopharmaceutical company’s stock valued at $1,682,000 after buying an additional 92,930 shares during the period. Jane Street Group LLC purchased a new stake in VBI Vaccines during the second quarter valued at about $173,000. Citadel Advisors LLC purchased a new stake in VBI Vaccines during the second quarter valued at about $31,000. Vanguard Group Inc. boosted its holdings in shares of VBI Vaccines by 12.4% during the second quarter. Vanguard Group Inc. now owns 1,356,944 shares of the biopharmaceutical company’s stock worth $1,587,000 after purchasing an additional 149,690 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of VBI Vaccines by 2,089.1% during the second quarter. BlackRock Inc. now owns 4,224,285 shares of the biopharmaceutical company’s stock worth $4,943,000 after purchasing an additional 4,031,318 shares during the period. Hedge funds and other institutional investors own 46.03% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Story: Bid-Ask Spread
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.